Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
23 Feb 2023
23 Feb 2023
Historique:
received:
05
09
2022
accepted:
09
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authorized for marketing in South Korea under the trade name SKYCovione
Identifiants
pubmed: 36823160
doi: 10.1038/s41541-023-00622-0
pii: 10.1038/s41541-023-00622-0
pmc: PMC9947939
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Informations de copyright
© 2023. The Author(s).
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
J Clin Invest. 2022 Oct 3;132(19):
pubmed: 35943810
Lancet. 2007 Aug 18;370(9587):580-9
pubmed: 17707753
NPJ Vaccines. 2022 Jun 28;7(1):71
pubmed: 35764661
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
World J Hepatol. 2015 Aug 28;7(18):2127-32
pubmed: 26328023
Vet Pathol. 2022 Jul;59(4):648-660
pubmed: 35521761
J Immunol. 2008 Jan 15;180(2):948-56
pubmed: 18178835
Nat Commun. 2021 Jan 14;12(1):372
pubmed: 33446655
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
J Virol. 2021 Mar 10;95(11):
pubmed: 33692201
Sci Immunol. 2022 Nov 18;7(77):eabq7647
pubmed: 35943359
J Virol. 2021 Jan 20;95(8):
pubmed: 33472939
Science. 2016 Jul 22;353(6297):389-94
pubmed: 27463675
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
PLoS One. 2008 Jan 02;3(1):e1401
pubmed: 18167560
NPJ Vaccines. 2021 May 13;6(1):70
pubmed: 33986287
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Sci Rep. 2021 Jul 21;11(1):14917
pubmed: 34290317
J Virol. 2021 Mar 16;95(11):
pubmed: 33727331
Cell. 2022 Apr 28;185(9):1556-1571.e18
pubmed: 35447072
Elife. 2020 Aug 04;9:
pubmed: 32748788
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33909009
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Cell Host Microbe. 2021 Feb 10;29(2):236-249.e6
pubmed: 33357418
J Biomed Sci. 2022 Jul 7;29(1):49
pubmed: 35799178
Adv Drug Deliv Rev. 2021 Mar;170:71-82
pubmed: 33421475
EClinicalMedicine. 2022 Jul 22;51:101569
pubmed: 35879941
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Cell. 2022 Apr 28;185(9):1549-1555.e11
pubmed: 35427477
EBioMedicine. 2022 Sep;83:104196
pubmed: 35932641
Cell. 2021 Oct 14;184(21):5432-5447.e16
pubmed: 34619077
JCI Insight. 2021 Apr 28;6(10):
pubmed: 33908897
N Engl J Med. 2022 Feb 10;386(6):531-543
pubmed: 34910859
Cell Rep Med. 2021 Apr 20;2(4):100230
pubmed: 33754147
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956